AXIS 2: AX200 for the Treatment of Ischemic Stroke - A Multinational, Multicenter, Randomized, Doubleblind, Placebo-controlled Phase II Trial
AXIS 2: AX200 for the Treatment of Ischemic Stroke - A Multinational, Multicenter, Randomized, Doubleblind, Placebo-controlled Phase II Trial
The purpose of this study is to assess the efficacy of AX200 (filgrastim) in the treatment of acute ischemic stroke and to assess the safety and tolerability of AX200.
Major Inclusion Criteria:
Major Exclusion Criteria:
Plzeň - Lochotín, 304 60, Czechia
Berlin, 12200, Germany
Gdansk, 80-803, Poland
Lodz, 90-549, Poland
Madrid, 28034, Spain